Clinical Trial

NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-10-05.
Status change: Not Yet Recruiting → Recruiting 2024-08-13
Trial Details
NCT Number NCT05572801
Lead Sponsor Aarhus University Hospital
Collaborators: Danish Comprehensive Cancer Center, Nordic Cancer Union, The regions medicine- and treatment funds
Conditions Anal Cancer
Enrollment 400 participants
Start Date 2023-08-02
Primary Completion 2026-06-01 (estimated)
Study Completion 2031-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-14